The Oxford-AstraZeneca vaccine has been linked to rare side effects such as Thrombosis, causing major concerns globally. With India having administered the Covishield vaccine to a large part of its population, there are growing worries about potential risks. Actor Shreyas Talpade, who recently suffered a cardiac arrest, has raised the question of whether it could be linked to the vaccine, posing a looming threat.
An Indian couple is seeking legal action against pharma giant AstraZeneca and Indian manufacturer Serum Institute of India (SII) for their daughter's death after receiving the Covishield vaccine. The couple claims that the vaccine caused her death and other serious injuries, including a rare blood clotting disorder. They are also calling out the government and regulatory bodies for not stopping the vaccine's rollout earlier despite reports of adverse events. If justice is not served, they plan to file additional lawsuits against all parties involved.
AstraZeneca, a British pharmaceutical company, has admitted in court that its COVID-19 vaccine, used in India under the name Covishield, can cause a rare side effect of blood clotting and low platelet count. While the company faces a lawsuit for severe harm and deaths caused by the vaccine, experts assure that the benefits of vaccination still outweigh the risks and TTS is more rare in Indians and South Asians. However, Indian patients may not be able to join the British petition due to legal hurdles.
AstraZeneca has for the first time officially acknowledged in court documents that its Covid-19 vaccine, sold as Covishield in India and Vaxzevria elsewhere, could cause a rare side-effect called Thrombosis Thrombocytopenia Syndrome (TTS). This comes after a UK-based man, Jamie Scott, was left with a permanent brain injury due to blood clotting and low platelet count after receiving the vaccine. AstraZeneca is now facing 51 legal cases in the UK with victims seeking up to 100 million British pounds in compensation. The company, however, has contested these claims but has accepted that the vaccine can cause TTS in very rare cases.
The makers of the Covishield vaccine, AstraZeneca, have acknowledged for the first time that the vaccine may lead to a rare side effect called Thrombosis with Thrombocytopenia Syndrome (TTS). This comes as the company is being sued in a class action and could result in a significant legal payout. Public health experts explain that TTS is a rare condition that has been observed as a potential adverse effect of certain COVID-19 vaccines, including Covishield. They also stress the importance of early detection and treatment of TTS for recovery, and believe that AstraZeneca's admission could lead to enhanced safety monitoring and regulatory oversight for vaccines.
A class action lawsuit has been filed against AstraZeneca in the UK after court documents revealed that the company's Covid vaccine, Covishield, can cause a rare side effect known as TTS. This condition, characterized by blood clots and low platelet count, has resulted in serious injuries and deaths for some patients who received the vaccine. Despite the company's admission, AstraZeneca maintains that the vaccine is not "defective" and that TTS can occur even without vaccination. The lawsuit seeks damages of up to 100 million pounds from the pharma giant.
In a shocking revelation, Reuters News has reported that Serum Institute, the manufacturer of Covishield vaccine, donated a whopping Rs 52 crore to India's ruling party, BJP, within a span of just 48 hours through electoral bonds. This news has emerged after the Supreme Court's recent order to make the details of all electoral bond donations public. While the Centre had given monopoly rights to Serum Institute for manufacturing the Covid-19 vaccine, this alleged donation has raised concerns about potential corruption and exploitation of the current pandemic situation for political gains. The Election Commission is expected to publish the bond data before March 15, bringing the truth to light.